Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of director share transactions rather than a financial performance report.
Material Changes
On June 30, 2011, Non-Executive Directors were provisionally allocated awards over Ordinary shares and American Depository Shares (ADSs) for the service period of April 1, 2011, to June 30, 2011. The allocation price was set at £13.20 per Ordinary share and $42.43 per ADS. These allocations were communicated to the Company and the Directors on July 1, 2011.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of director share interests in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Type: Provisional allocation of share awards to Non-Executive Directors.
- Allocation Date: June 30, 2011 (notified July 1, 2011).
- Share Price Basis: £13.20 per Ordinary share; $42.43 per ADS.
- Participants: Includes Sir Christopher Gent, Prof. Sir Roy Anderson, Dr Stephanie Burns, Ms Stacey Cartwright, Mr Lawrence Culp, Sir Crispin Davis, Ms Judy Lewent, Sir Deryck Maughan, Mr James Murdoch, Dr Daniel Podolsky, Mr Tom de Swaan, and Sir Robert Wilson.
- Financial Data: No operational or financial performance metrics are included in this specific filing.